Pair-matched study of cryopreserved versus native graft in adult and pediatric recipients of allogeneic hematopoietic stem cell transplantation

Babenko, Elena V.; Moiseev, Ivan S.; Kanunnikov, Mikhail; Alyanskiy, Alexandr L.; Pevcov, Dmitrii E.; Фролова, А. В.; Osipova, Anna A.; Быкова, Т А; Paina, Olesya V.; Darskaya, Elena I.; Zubarovskaya, Ludmila; Bondarenko, Sergey N.; Markova, Inna V.; Afanasyev, Boris

doi:10.18620/ctt-1866-8836-2018-7-2-45-53

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we tried to use non-cryopreserved allogeneic grafts whenever possible, and succeeded in 90% of allografts. The reason for this practice is provided by the data from our center, published in 2018 showing higher frequency of primary graft failure with a cryopreserved allogeneic graft [6]. COVID-19positive cases were recorded in eight donors, of which 6 were scheduled for adult patients and 2, for children.…”

Section: Transplant Activity In 2020mentioning

confidence: 99%

Journey of a hematopoietic stem cell transplantation center through COVID-19 pandemic: one-year experience

Siniaev¹,

Popova²,

Rogacheva³

et al. 2022

CTT

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is a life-saving procedure for oncological, hematological and non-malignant disorders. Despite global trend for a decrease of transplantation activity in view of the COVID-19 pandemic, we tried to maintain it by taking preventive measures and optimizing infection control in our center. Patients and methodsThis is an observational study. We collected the performance data of our transplant center from April 2020 to July 2021, i.e., during two waves of the pandemic. The main objectives were to study the influence of COVID-19 pandemic on the workflow of the HSCT center, including morbidity among employees and HSCT recipients, as well as on the transplant activity. ResultsThe first case of COVID-19 infection in St. Petersburg was recorded on March 8, 2020. On March 30, 2020, a national lockdown had been imposed in the Russian Federation. The second wave of COVID-19 started in October 2020. Weekly screening of staff and patients was the main diagnostic tool, in addition to the governmental requirements. In sum, a total of 21702 PCR tests for SARS-CoV-2 were performed over the study period. As for July 1, 2021, 69.7% of employees became immune to the virus, due to previous COVID-19 disease, or by vaccination. In 2020, we managed to perform 419 HSCT, including 136 autologous and 283 allogeneic transplants. For comparison, 415 HSCTs were carried out in 2019, with 144 autologous and 271 allogeneic transplants. In 2020, the HSC donorship was shifted towards unrelated donors from the Russian Registry and haploidentical donors. Incidence of COVID-19 among HSCT recipients between April 2020 and July 2021 was 7.3% (n=39), being 8.6% (n=31) after allogeneic HSCT, and 4.5% (n=8) following auto-HSCT. The median age of patients with COVID-19 was 27 years (4-66). The median term for the COVID-19 onset was 68 days post-transplant (-1 to +2093). In most patients -29 (74.3%) the HCT CI comorbidity index at the time of transplantation was 0. The stem cell source were either peripheral blood stem cells (n=22, 56.4%), or bone marrow (n=17, 43.6%). Most of the patients achieved complete remission of the underlying disease at the time of HSCT (n=30, 76.9%). The overall 100-day survival rate among HSCT recipients since the diagnosis of the COVID-19 was 79.5% (95% CI 0.609 -0.884). The mortality rate was 20.5% (n=8). The causes of death were as follows: COVID-19 -50% (n=4); secondary infectious complications, 25% (n=2); relapse of the underlying disease, 12.5% (n=1);

show abstract

Section: Transplant Activity In 2020mentioning

confidence: 99%

Journey of a hematopoietic stem cell transplantation center through COVID-19 pandemic: one-year experience

Siniaev¹,

Popova²,

Rogacheva³

et al. 2022

CTT

View full text Add to dashboard Cite

show abstract

“…The results of these studies are contradictory and mostly were limited by the data of HLA-matched bone marrow transplantations (BMT) [1][2][3][4]. At the same time, the use of cryopreservation in haplo-SCT has practically not been studied.…”

Section: Introductionmentioning

confidence: 99%

Graft preservation in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide: single center experience

Badaev,

Zammoeva,

Chistyakov

et al. 2023

CTT

View full text Add to dashboard Cite

Haploidentical stem cell transplantation (haplo-SCT) is often used as a treatment option in the absence of HLAmatched donor. Cryopreservation of the graft allows pre-preparation of the bone marrow, which has become especially important during the COVID-19 epidemic. As cryopreservation remains to be relatively less studied in the context of haplo-SCT, we conductеd a retrospective analysis of its feasibility in our patients. Medical records search identified 113 patients with various oncohematological diseases, who received haplo-SCT with (n=68) or without (n=64) graft cryopreservation between 2015 and 2020. Graft-versus-host disease (GvHD) prevention with post-transplant cyclophosphamide was used in all patients. Both cohorts of patients were comparable in terms of recipient age and gender, disease activity, graft source, and rates of major AB0 incompatibility. Age of donors was significantly higher in cryopreserved graft recipients (45 vs 37 years, p=0.017). Rates of acute and chronic GvHD, disease relapse, as well as PFS and OS did not significantly differ between the two studied cohorts. There was also no difference in terms of granulocyte and thrombocyte recovery. Although, in univariate analysis, cryopreservation significantly increased risk of graft rejection (34.3% vs 15.4%, p=0.02) and secondary graft failure (19.5% vs 4.4%, p=0.02), in multivariate analysis, there was only a trend towards increased risk of secondary graft failure with cryopreservation (p=0.096). As a summary, our data suggest that graft cryopreservation during haplo-SCT with post-transplant cyclophosphamide has no negative impact on key SCT endpoints.

show abstract

Pair-matched study of cryopreserved versus native graft in adult and pediatric recipients of allogeneic hematopoietic stem cell transplantation

Cited by 2 publications

References 19 publications

Journey of a hematopoietic stem cell transplantation center through COVID-19 pandemic: one-year experience

Journey of a hematopoietic stem cell transplantation center through COVID-19 pandemic: one-year experience

Graft preservation in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide: single center experience

Contact Info

Product

Resources

About